Identification of Early Markers of Response and Resistance to Trastuzumab
NCT01834950
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
25
Enrollment
OTHER
Sponsor class
Conditions
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
Interventions
OTHER:
Blood test
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators
[object Object]